Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors

Summary

This study evaluates red-blood-cell membrane-coated polymeric nanoparticles as an immune-compatible carrier for chemotherapy of solid lymphoma tumors. A biodegradable nanoparticle core was cloaked with natural erythrocyte membrane to reduce immune recognition and extend circulation, then loaded with doxorubicin as a model anticancer drug. In a murine lymphoma model, the biomimetic carrier delivered drug to tumor sites and inhibited tumor growth more effectively than conventional free doxorubicin. The formulation also showed favorable immunocompatibility and a better safety profile than the free drug in the reported assessments. The principal result is that a simple biological coating can combine prolonged systemic behavior with effective cargo delivery while reducing some treatment-associated burden. This supports membrane cloaking as a foundation for safer cancer nanocarriers rather than merely a targeting decoration. However, the abstract does not report nanoparticle dose, tumor accumulation, circulation half-life, tumor-growth values, survival, sample size, or specific immune and safety measurements. It is unclear whether improved efficacy reflects exposure, tumor localization, altered release, or all three. Evidence is limited to doxorubicin and one mouse lymphoma model; membrane sourcing, pathogen safety, repeated administration, scale-up, comparison with modern formulations, and human benefit remain untested.